| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 63 | 2024 | 875 | 8.010 |
Why?
|
| Kidney Tubules, Proximal | 50 | 2023 | 130 | 7.630 |
Why?
|
| Kidney | 75 | 2024 | 1497 | 6.460 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 28 | 2021 | 63 | 4.550 |
Why?
|
| Ischemia | 44 | 2015 | 422 | 4.460 |
Why?
|
| Albumins | 9 | 2023 | 119 | 3.190 |
Why?
|
| Glomerular Filtration Rate | 24 | 2024 | 765 | 3.150 |
Why?
|
| Nephrology | 13 | 2021 | 60 | 2.760 |
Why?
|
| Kidney Glomerulus | 15 | 2022 | 125 | 2.150 |
Why?
|
| Renal Insufficiency, Chronic | 9 | 2022 | 668 | 2.090 |
Why?
|
| Intravital Microscopy | 8 | 2023 | 24 | 2.060 |
Why?
|
| Actins | 22 | 2009 | 425 | 1.930 |
Why?
|
| Gentamicins | 16 | 2012 | 50 | 1.860 |
Why?
|
| Renal Circulation | 15 | 2015 | 75 | 1.700 |
Why?
|
| Rats | 77 | 2024 | 5584 | 1.690 |
Why?
|
| Albuminuria | 10 | 2022 | 189 | 1.630 |
Why?
|
| Plasma Volume | 5 | 2022 | 20 | 1.620 |
Why?
|
| Creatinine | 15 | 2021 | 515 | 1.600 |
Why?
|
| Fluorescent Dyes | 15 | 2020 | 333 | 1.390 |
Why?
|
| Cytoskeleton | 13 | 2004 | 192 | 1.350 |
Why?
|
| Endocytosis | 15 | 2023 | 168 | 1.330 |
Why?
|
| Diagnostic Imaging | 8 | 2014 | 337 | 1.320 |
Why?
|
| Animals | 132 | 2024 | 38030 | 1.190 |
Why?
|
| Adenosine Triphosphate | 13 | 2018 | 500 | 1.140 |
Why?
|
| Serum Albumin | 6 | 2020 | 147 | 1.110 |
Why?
|
| Kidney Diseases | 12 | 2021 | 425 | 1.110 |
Why?
|
| Rats, Sprague-Dawley | 40 | 2024 | 2524 | 1.100 |
Why?
|
| Kidney Function Tests | 5 | 2012 | 156 | 1.030 |
Why?
|
| Sepsis | 8 | 2018 | 664 | 0.990 |
Why?
|
| Microvilli | 16 | 2022 | 75 | 0.960 |
Why?
|
| Endothelium, Vascular | 8 | 2015 | 956 | 0.860 |
Why?
|
| Rats, Wistar | 14 | 2022 | 450 | 0.830 |
Why?
|
| Renal Insufficiency | 4 | 2023 | 172 | 0.810 |
Why?
|
| Microscopy, Fluorescence | 10 | 2020 | 408 | 0.800 |
Why?
|
| Dextrans | 5 | 2018 | 84 | 0.800 |
Why?
|
| Reperfusion Injury | 8 | 2024 | 293 | 0.790 |
Why?
|
| Clathrin | 2 | 2023 | 26 | 0.780 |
Why?
|
| Microscopy, Video | 4 | 2008 | 24 | 0.780 |
Why?
|
| Renal Dialysis | 9 | 2014 | 466 | 0.770 |
Why?
|
| Ureteral Obstruction | 2 | 2022 | 63 | 0.750 |
Why?
|
| Intra-Abdominal Hypertension | 1 | 2022 | 7 | 0.730 |
Why?
|
| Azotemia | 1 | 2022 | 13 | 0.720 |
Why?
|
| Receptors, Fc | 3 | 2020 | 54 | 0.700 |
Why?
|
| Career Choice | 3 | 2013 | 234 | 0.690 |
Why?
|
| Microscopy, Confocal | 8 | 2010 | 319 | 0.680 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2020 | 202 | 0.660 |
Why?
|
| Humans | 104 | 2024 | 145475 | 0.630 |
Why?
|
| Endothelial Cells | 4 | 2015 | 874 | 0.620 |
Why?
|
| Rhodamines | 2 | 2018 | 19 | 0.620 |
Why?
|
| Anti-Bacterial Agents | 10 | 2006 | 1923 | 0.620 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 1061 | 0.620 |
Why?
|
| LLC-PK1 Cells | 11 | 2006 | 18 | 0.610 |
Why?
|
| Bacterial Infections | 5 | 2018 | 246 | 0.600 |
Why?
|
| Indocyanine Green | 1 | 2019 | 42 | 0.580 |
Why?
|
| Critical Illness | 4 | 2018 | 900 | 0.560 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2019 | 165 | 0.550 |
Why?
|
| Fluorescein | 1 | 2018 | 24 | 0.550 |
Why?
|
| Microfilament Proteins | 5 | 2003 | 135 | 0.550 |
Why?
|
| Aminoglycosides | 5 | 2023 | 30 | 0.550 |
Why?
|
| Point-of-Care Systems | 2 | 2018 | 189 | 0.540 |
Why?
|
| RNA, Small Interfering | 4 | 2021 | 637 | 0.530 |
Why?
|
| Golgi Apparatus | 4 | 2006 | 99 | 0.530 |
Why?
|
| Cell Membrane | 17 | 2019 | 707 | 0.530 |
Why?
|
| Epithelium | 13 | 2020 | 310 | 0.520 |
Why?
|
| Actin Cytoskeleton | 4 | 2003 | 103 | 0.480 |
Why?
|
| Male | 79 | 2024 | 72843 | 0.470 |
Why?
|
| Xanthenes | 5 | 2013 | 10 | 0.450 |
Why?
|
| Cell Membrane Permeability | 2 | 2013 | 88 | 0.440 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2014 | 14 | 0.440 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 26 | 0.440 |
Why?
|
| Swine | 13 | 2011 | 825 | 0.430 |
Why?
|
| Metabolic Clearance Rate | 3 | 2013 | 115 | 0.430 |
Why?
|
| Mitochondria | 3 | 2018 | 992 | 0.430 |
Why?
|
| Actin Depolymerizing Factors | 5 | 2006 | 8 | 0.420 |
Why?
|
| Biomarkers | 14 | 2022 | 4295 | 0.410 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 10 | 1995 | 55 | 0.410 |
Why?
|
| Kidney Tubules, Distal | 3 | 2012 | 5 | 0.410 |
Why?
|
| Microvessels | 1 | 2015 | 97 | 0.390 |
Why?
|
| Photons | 5 | 2011 | 67 | 0.380 |
Why?
|
| Nephrons | 2 | 2011 | 23 | 0.370 |
Why?
|
| Biomedical Research | 7 | 2021 | 717 | 0.370 |
Why?
|
| Capillary Permeability | 5 | 2017 | 132 | 0.360 |
Why?
|
| Fellowships and Scholarships | 2 | 2013 | 354 | 0.350 |
Why?
|
| Optical Fibers | 1 | 2011 | 17 | 0.350 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2012 | 534 | 0.350 |
Why?
|
| Polysaccharides | 2 | 2021 | 86 | 0.340 |
Why?
|
| Image Enhancement | 2 | 2010 | 200 | 0.330 |
Why?
|
| Anemia | 2 | 2002 | 191 | 0.320 |
Why?
|
| Health Policy | 1 | 2013 | 400 | 0.310 |
Why?
|
| Antimycin A | 4 | 2003 | 14 | 0.310 |
Why?
|
| Biological Transport | 8 | 2022 | 424 | 0.310 |
Why?
|
| Cofilin 1 | 2 | 2009 | 5 | 0.310 |
Why?
|
| Time Factors | 19 | 2020 | 7123 | 0.310 |
Why?
|
| Tissue Distribution | 9 | 2024 | 335 | 0.300 |
Why?
|
| Kidney Cortex | 5 | 2014 | 27 | 0.300 |
Why?
|
| Kidney Tubules | 5 | 2020 | 118 | 0.300 |
Why?
|
| Precision Medicine | 1 | 2014 | 459 | 0.300 |
Why?
|
| Education, Medical, Graduate | 2 | 2013 | 562 | 0.300 |
Why?
|
| Microscopy | 3 | 2022 | 147 | 0.300 |
Why?
|
| Cell Line | 12 | 2018 | 2823 | 0.290 |
Why?
|
| Thrombomodulin | 1 | 2009 | 15 | 0.290 |
Why?
|
| Epithelial Cells | 6 | 2019 | 1131 | 0.290 |
Why?
|
| Microcirculation | 6 | 2010 | 142 | 0.280 |
Why?
|
| Membrane Lipids | 8 | 2001 | 82 | 0.280 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 4560 | 0.280 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2009 | 56 | 0.280 |
Why?
|
| Receptors, Cell Surface | 3 | 2022 | 372 | 0.280 |
Why?
|
| Clathrin-Coated Vesicles | 1 | 2008 | 5 | 0.270 |
Why?
|
| beta 2-Microglobulin | 5 | 2009 | 48 | 0.270 |
Why?
|
| Fluorescein-5-isothiocyanate | 3 | 2017 | 36 | 0.270 |
Why?
|
| Luminescent Proteins | 3 | 2007 | 186 | 0.260 |
Why?
|
| Mice | 17 | 2024 | 18329 | 0.260 |
Why?
|
| Cell Polarity | 4 | 1998 | 137 | 0.260 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2008 | 152 | 0.250 |
Why?
|
| Folic Acid | 2 | 2009 | 198 | 0.250 |
Why?
|
| Rats, Inbred Strains | 12 | 2020 | 321 | 0.250 |
Why?
|
| Erythropoietin | 2 | 2012 | 100 | 0.240 |
Why?
|
| Cytokines | 3 | 2018 | 2067 | 0.240 |
Why?
|
| Klebsiella pneumoniae | 1 | 2006 | 47 | 0.240 |
Why?
|
| Phospholipids | 5 | 2001 | 214 | 0.240 |
Why?
|
| Cystatin C | 2 | 2021 | 66 | 0.240 |
Why?
|
| Bacillus subtilis | 1 | 2006 | 65 | 0.230 |
Why?
|
| Diabetic Nephropathies | 3 | 2017 | 322 | 0.230 |
Why?
|
| Microscopy, Polarization | 1 | 2005 | 30 | 0.230 |
Why?
|
| Injections, Intravenous | 4 | 2018 | 197 | 0.230 |
Why?
|
| Alpha-Globulins | 2 | 2024 | 20 | 0.230 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2010 | 779 | 0.220 |
Why?
|
| Physicians | 2 | 2011 | 955 | 0.220 |
Why?
|
| Iohexol | 2 | 2018 | 23 | 0.220 |
Why?
|
| Mass Screening | 1 | 2013 | 1360 | 0.220 |
Why?
|
| MicroRNAs | 1 | 2011 | 686 | 0.220 |
Why?
|
| Disease Progression | 7 | 2017 | 2864 | 0.210 |
Why?
|
| Blood Coagulation | 3 | 2018 | 274 | 0.210 |
Why?
|
| Adenoviridae | 4 | 2007 | 199 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 1419 | 0.210 |
Why?
|
| Kidney Failure, Chronic | 4 | 2011 | 599 | 0.210 |
Why?
|
| Inulin | 2 | 2017 | 12 | 0.210 |
Why?
|
| Protein C | 3 | 2009 | 54 | 0.210 |
Why?
|
| Female | 25 | 2021 | 78845 | 0.210 |
Why?
|
| Tropomyosin | 1 | 2003 | 10 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 1505 | 0.200 |
Why?
|
| Heart Failure | 3 | 2022 | 2326 | 0.200 |
Why?
|
| Secretory Vesicles | 1 | 2003 | 24 | 0.200 |
Why?
|
| Coloring Agents | 3 | 2019 | 89 | 0.200 |
Why?
|
| Endoplasmic Reticulum | 2 | 2003 | 264 | 0.200 |
Why?
|
| Sodium | 5 | 2009 | 198 | 0.190 |
Why?
|
| Liver | 2 | 2022 | 1896 | 0.190 |
Why?
|
| Models, Biological | 8 | 2014 | 1764 | 0.190 |
Why?
|
| Species Specificity | 1 | 2023 | 546 | 0.180 |
Why?
|
| Asparagine | 1 | 2022 | 35 | 0.180 |
Why?
|
| Cells, Cultured | 9 | 2019 | 4148 | 0.180 |
Why?
|
| Kinetics | 8 | 2008 | 1567 | 0.180 |
Why?
|
| Podocytes | 3 | 2020 | 80 | 0.180 |
Why?
|
| Destrin | 4 | 2003 | 4 | 0.180 |
Why?
|
| Nucleotides | 1 | 2002 | 129 | 0.170 |
Why?
|
| Membranes, Artificial | 4 | 1995 | 68 | 0.170 |
Why?
|
| Leukocytes | 4 | 2011 | 296 | 0.170 |
Why?
|
| Protein Transport | 4 | 2010 | 442 | 0.170 |
Why?
|
| Heart | 2 | 2019 | 626 | 0.170 |
Why?
|
| Microscopy, Electron | 7 | 2007 | 414 | 0.170 |
Why?
|
| Stress, Mechanical | 3 | 2019 | 494 | 0.170 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2002 | 365 | 0.170 |
Why?
|
| Hypertension | 2 | 2017 | 1273 | 0.170 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2020 | 6 | 0.170 |
Why?
|
| Academies and Institutes | 1 | 2021 | 61 | 0.160 |
Why?
|
| Gene Transfer Techniques | 4 | 2007 | 187 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2018 | 666 | 0.160 |
Why?
|
| Scattering, Small Angle | 2 | 2020 | 22 | 0.160 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 2010 | 48 | 0.160 |
Why?
|
| Capillary Leak Syndrome | 1 | 2020 | 12 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2011 | 1267 | 0.160 |
Why?
|
| X-Ray Diffraction | 2 | 2020 | 83 | 0.160 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2019 | 583 | 0.160 |
Why?
|
| Phosphorylation | 5 | 2014 | 1707 | 0.150 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 118 | 0.150 |
Why?
|
| Myosins | 2 | 1997 | 132 | 0.150 |
Why?
|
| Immunotoxins | 1 | 2020 | 55 | 0.150 |
Why?
|
| Sulfolobus solfataricus | 1 | 2019 | 9 | 0.150 |
Why?
|
| Solubility | 4 | 2009 | 240 | 0.150 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 69 | 0.150 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 183 | 0.150 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 449 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 2930 | 0.150 |
Why?
|
| Immunohistochemistry | 8 | 2012 | 1716 | 0.150 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 2009 | 26 | 0.150 |
Why?
|
| Archaeal Proteins | 1 | 2019 | 50 | 0.150 |
Why?
|
| Organizational Policy | 2 | 2009 | 78 | 0.150 |
Why?
|
| Conflict of Interest | 2 | 2009 | 54 | 0.140 |
Why?
|
| Prognosis | 2 | 2020 | 4316 | 0.140 |
Why?
|
| Basigin | 1 | 2018 | 24 | 0.140 |
Why?
|
| Nephritis | 1 | 2018 | 22 | 0.140 |
Why?
|
| Commerce | 2 | 2009 | 80 | 0.140 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2019 | 79 | 0.140 |
Why?
|
| Lipid A | 1 | 2018 | 27 | 0.140 |
Why?
|
| Intercellular Junctions | 4 | 1993 | 35 | 0.140 |
Why?
|
| Octoxynol | 4 | 2003 | 12 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2022 | 572 | 0.140 |
Why?
|
| International Cooperation | 4 | 2021 | 197 | 0.140 |
Why?
|
| Renal Reabsorption | 2 | 2017 | 4 | 0.140 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 3 | 2014 | 6 | 0.140 |
Why?
|
| Alkaline Phosphatase | 1 | 2018 | 144 | 0.140 |
Why?
|
| Sulfones | 2 | 1989 | 127 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2021 | 341 | 0.130 |
Why?
|
| Cell Adhesion Molecules | 1 | 1999 | 181 | 0.130 |
Why?
|
| Immunoblotting | 3 | 2003 | 295 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2021 | 8057 | 0.130 |
Why?
|
| Recombinant Proteins | 4 | 2020 | 1368 | 0.130 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 4 | 2003 | 331 | 0.130 |
Why?
|
| Proteinuria | 4 | 2022 | 104 | 0.130 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 72 | 0.130 |
Why?
|
| Ischemic Preconditioning | 1 | 2018 | 47 | 0.130 |
Why?
|
| Endpoint Determination | 3 | 2012 | 85 | 0.130 |
Why?
|
| Fluid Therapy | 2 | 2017 | 155 | 0.130 |
Why?
|
| Lysosomes | 2 | 1998 | 131 | 0.130 |
Why?
|
| Glycosylation | 3 | 2022 | 173 | 0.130 |
Why?
|
| Proteins | 2 | 2001 | 1023 | 0.130 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2017 | 7 | 0.130 |
Why?
|
| DNA Repair | 1 | 2019 | 254 | 0.130 |
Why?
|
| Receptors, Vitronectin | 1 | 2017 | 5 | 0.130 |
Why?
|
| Models, Animal | 3 | 2019 | 393 | 0.130 |
Why?
|
| Fluoresceins | 1 | 2017 | 48 | 0.130 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2018 | 74 | 0.130 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 42 | 0.120 |
Why?
|
| Spectrin | 1 | 1996 | 14 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2010 | 899 | 0.120 |
Why?
|
| Hydrodynamics | 1 | 2017 | 50 | 0.120 |
Why?
|
| Renal Agents | 1 | 2016 | 5 | 0.120 |
Why?
|
| Oligosaccharides | 1 | 2017 | 60 | 0.120 |
Why?
|
| DNA Damage | 1 | 2019 | 437 | 0.120 |
Why?
|
| Optical Imaging | 1 | 2017 | 61 | 0.120 |
Why?
|
| Early Medical Intervention | 1 | 2017 | 62 | 0.120 |
Why?
|
| Renal Replacement Therapy | 5 | 2008 | 100 | 0.120 |
Why?
|
| Green Fluorescent Proteins | 4 | 2006 | 407 | 0.120 |
Why?
|
| Intracellular Membranes | 2 | 1994 | 77 | 0.120 |
Why?
|
| Hemodynamics | 2 | 2015 | 1118 | 0.120 |
Why?
|
| Apoptosis | 4 | 2009 | 2440 | 0.120 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 205 | 0.120 |
Why?
|
| Cricetulus | 1 | 2016 | 118 | 0.120 |
Why?
|
| United States | 6 | 2013 | 16098 | 0.120 |
Why?
|
| CHO Cells | 1 | 2016 | 169 | 0.120 |
Why?
|
| Polymers | 3 | 2002 | 485 | 0.120 |
Why?
|
| Cisplatin | 3 | 2009 | 345 | 0.120 |
Why?
|
| Dietary Proteins | 1 | 2017 | 135 | 0.110 |
Why?
|
| Cricetinae | 1 | 2016 | 305 | 0.110 |
Why?
|
| Pentoxifylline | 1 | 1995 | 23 | 0.110 |
Why?
|
| Chromatography, Liquid | 3 | 2022 | 450 | 0.110 |
Why?
|
| Lipopolysaccharides | 2 | 2010 | 858 | 0.110 |
Why?
|
| Glycation End Products, Advanced | 1 | 2016 | 81 | 0.110 |
Why?
|
| Fluorobenzenes | 1 | 2015 | 17 | 0.110 |
Why?
|
| Hemorheology | 1 | 2015 | 24 | 0.110 |
Why?
|
| Bacterial Proteins | 1 | 2001 | 967 | 0.110 |
Why?
|
| Heptanoic Acids | 1 | 2015 | 67 | 0.110 |
Why?
|
| Aged | 8 | 2021 | 26153 | 0.110 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2010 | 414 | 0.110 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2014 | 27 | 0.100 |
Why?
|
| Detergents | 3 | 2003 | 43 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2016 | 218 | 0.100 |
Why?
|
| Transcytosis | 1 | 2014 | 7 | 0.100 |
Why?
|
| Basement Membrane | 1 | 1994 | 32 | 0.100 |
Why?
|
| Interleukin-6 | 3 | 2009 | 776 | 0.100 |
Why?
|
| Capillaries | 1 | 2015 | 125 | 0.100 |
Why?
|
| Pericytes | 1 | 2014 | 42 | 0.100 |
Why?
|
| Cholesterol | 2 | 1987 | 408 | 0.100 |
Why?
|
| Genetic Vectors | 3 | 2018 | 335 | 0.100 |
Why?
|
| Endothelium | 1 | 2014 | 119 | 0.100 |
Why?
|
| Necrosis | 3 | 2003 | 244 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 5983 | 0.100 |
Why?
|
| Pyrroles | 1 | 2015 | 220 | 0.100 |
Why?
|
| Patient Selection | 3 | 2012 | 738 | 0.100 |
Why?
|
| Forecasting | 2 | 2015 | 390 | 0.100 |
Why?
|
| Organizational Innovation | 1 | 2014 | 119 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 1480 | 0.100 |
Why?
|
| Cell Adhesion | 3 | 2011 | 451 | 0.100 |
Why?
|
| Critical Care | 4 | 2016 | 702 | 0.100 |
Why?
|
| Machine Learning | 1 | 2019 | 587 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2015 | 224 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2021 | 2062 | 0.100 |
Why?
|
| Escherichia coli | 2 | 2008 | 835 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2017 | 1779 | 0.090 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 121 | 0.090 |
Why?
|
| Subcellular Fractions | 2 | 2006 | 73 | 0.090 |
Why?
|
| Escherichia coli Infections | 2 | 2011 | 125 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5423 | 0.090 |
Why?
|
| Algorithms | 3 | 2010 | 1845 | 0.090 |
Why?
|
| Middle Aged | 7 | 2019 | 36215 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2021 | 288 | 0.090 |
Why?
|
| NAD | 1 | 2012 | 79 | 0.090 |
Why?
|
| Punctures | 1 | 2012 | 41 | 0.090 |
Why?
|
| Contrast Media | 1 | 2015 | 497 | 0.090 |
Why?
|
| Adult | 8 | 2019 | 40777 | 0.090 |
Why?
|
| Aluminum | 2 | 1989 | 43 | 0.090 |
Why?
|
| Wounds and Injuries | 2 | 2012 | 961 | 0.090 |
Why?
|
| Membrane Potentials | 2 | 1989 | 278 | 0.090 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2012 | 47 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 3413 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2018 | 847 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 892 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 368 | 0.090 |
Why?
|
| Young Adult | 2 | 2019 | 14219 | 0.090 |
Why?
|
| Risk Factors | 7 | 2016 | 10885 | 0.090 |
Why?
|
| Foreign Medical Graduates | 1 | 2011 | 7 | 0.090 |
Why?
|
| Capitation Fee | 1 | 2011 | 14 | 0.080 |
Why?
|
| Radiometry | 1 | 2011 | 56 | 0.080 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2011 | 4 | 0.080 |
Why?
|
| Cell Communication | 2 | 2007 | 328 | 0.080 |
Why?
|
| Cell Movement | 2 | 2011 | 959 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 2 | 2012 | 361 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2015 | 530 | 0.080 |
Why?
|
| Thorax | 1 | 2011 | 51 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 499 | 0.080 |
Why?
|
| Nephrectomy | 2 | 2015 | 163 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2012 | 351 | 0.080 |
Why?
|
| Hospitalization | 1 | 2001 | 2460 | 0.080 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2010 | 18 | 0.080 |
Why?
|
| Earthquakes | 1 | 2010 | 12 | 0.080 |
Why?
|
| Disaster Medicine | 1 | 2010 | 11 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2015 | 583 | 0.080 |
Why?
|
| Endothelin-1 | 1 | 2012 | 181 | 0.080 |
Why?
|
| Fimbriae, Bacterial | 1 | 2011 | 36 | 0.080 |
Why?
|
| Kidney Transplantation | 2 | 2010 | 712 | 0.080 |
Why?
|
| Glutathione | 1 | 2012 | 370 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2014 | 499 | 0.080 |
Why?
|
| Reimbursement Mechanisms | 1 | 2011 | 79 | 0.080 |
Why?
|
| Volunteers | 1 | 2010 | 39 | 0.080 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 207 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2013 | 402 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2015 | 1300 | 0.080 |
Why?
|
| Population Dynamics | 1 | 2011 | 142 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3623 | 0.080 |
Why?
|
| Informed Consent | 1 | 2012 | 198 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2010 | 2188 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 2187 | 0.080 |
Why?
|
| Membrane Proteins | 4 | 2008 | 1164 | 0.080 |
Why?
|
| Transfection | 2 | 2018 | 926 | 0.080 |
Why?
|
| Endosomes | 2 | 2004 | 140 | 0.080 |
Why?
|
| Dogs | 1 | 2011 | 458 | 0.080 |
Why?
|
| Nephrotic Syndrome | 2 | 2007 | 43 | 0.080 |
Why?
|
| Receptor, PAR-1 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cytosol | 2 | 2003 | 213 | 0.080 |
Why?
|
| Mesoderm | 1 | 2010 | 147 | 0.080 |
Why?
|
| Equipment Design | 1 | 2011 | 525 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 611 | 0.070 |
Why?
|
| Biological Transport, Active | 2 | 2001 | 69 | 0.070 |
Why?
|
| Physician Assistants | 1 | 2011 | 101 | 0.070 |
Why?
|
| Disaster Planning | 1 | 2010 | 103 | 0.070 |
Why?
|
| Delphi Technique | 2 | 2008 | 332 | 0.070 |
Why?
|
| Disease | 1 | 1990 | 96 | 0.070 |
Why?
|
| Xenopus laevis | 2 | 2006 | 104 | 0.070 |
Why?
|
| Nurse Practitioners | 1 | 2011 | 139 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2008 | 337 | 0.070 |
Why?
|
| Mentors | 1 | 2011 | 217 | 0.070 |
Why?
|
| Regional Blood Flow | 2 | 2010 | 514 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2004 | 531 | 0.070 |
Why?
|
| Interleukin-1alpha | 1 | 2009 | 57 | 0.070 |
Why?
|
| Cystatins | 1 | 2008 | 7 | 0.070 |
Why?
|
| Deferoxamine | 1 | 1988 | 27 | 0.070 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2009 | 76 | 0.070 |
Why?
|
| Terminology as Topic | 2 | 2008 | 257 | 0.070 |
Why?
|
| Vancomycin | 1 | 1989 | 94 | 0.070 |
Why?
|
| Furosemide | 2 | 2021 | 37 | 0.070 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2008 | 43 | 0.070 |
Why?
|
| Reperfusion | 2 | 2002 | 54 | 0.070 |
Why?
|
| Acute Disease | 2 | 2008 | 1036 | 0.070 |
Why?
|
| rho-Associated Kinases | 1 | 2009 | 82 | 0.070 |
Why?
|
| Amides | 1 | 2009 | 101 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 2588 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2121 | 0.070 |
Why?
|
| Perception | 1 | 2011 | 378 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 229 | 0.070 |
Why?
|
| Polycystic Kidney Diseases | 2 | 2002 | 71 | 0.070 |
Why?
|
| Receptors, Virus | 1 | 2008 | 95 | 0.070 |
Why?
|
| Lysine | 2 | 2020 | 305 | 0.070 |
Why?
|
| DNA Primers | 1 | 2009 | 505 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 333 | 0.070 |
Why?
|
| Staining and Labeling | 3 | 2020 | 153 | 0.070 |
Why?
|
| Erythrocyte Aggregation | 1 | 2007 | 4 | 0.070 |
Why?
|
| Mucous Membrane | 1 | 2008 | 128 | 0.060 |
Why?
|
| Multiprotein Complexes | 1 | 2008 | 172 | 0.060 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2007 | 25 | 0.060 |
Why?
|
| Optics and Photonics | 1 | 2007 | 37 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2007 | 31 | 0.060 |
Why?
|
| Membrane Fluidity | 1 | 1987 | 8 | 0.060 |
Why?
|
| Ligation | 1 | 2007 | 91 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2008 | 234 | 0.060 |
Why?
|
| Stem Cells | 1 | 2011 | 628 | 0.060 |
Why?
|
| Artifacts | 1 | 2007 | 143 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 45 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 162 | 0.060 |
Why?
|
| Proteomics | 3 | 2022 | 1188 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2007 | 101 | 0.060 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 200 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2009 | 2214 | 0.060 |
Why?
|
| Computer Systems | 1 | 2006 | 55 | 0.060 |
Why?
|
| Lim Kinases | 1 | 2006 | 5 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2009 | 1217 | 0.060 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2006 | 23 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 297 | 0.060 |
Why?
|
| Bacteria | 1 | 2012 | 765 | 0.060 |
Why?
|
| Radiography | 1 | 2008 | 852 | 0.060 |
Why?
|
| Angiostatins | 1 | 2005 | 3 | 0.060 |
Why?
|
| Endostatins | 1 | 2005 | 10 | 0.060 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 172 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2010 | 2507 | 0.060 |
Why?
|
| Base Sequence | 1 | 2009 | 2170 | 0.060 |
Why?
|
| Plasma | 1 | 2007 | 223 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2021 | 199 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2018 | 331 | 0.060 |
Why?
|
| Biocompatible Materials | 1 | 1989 | 429 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 372 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2012 | 386 | 0.050 |
Why?
|
| Cation Transport Proteins | 1 | 2006 | 118 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2769 | 0.050 |
Why?
|
| Pyridines | 1 | 2009 | 609 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2008 | 785 | 0.050 |
Why?
|
| Iodine Radioisotopes | 2 | 1995 | 136 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 592 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2803 | 0.050 |
Why?
|
| Leucine Zippers | 1 | 2003 | 13 | 0.050 |
Why?
|
| Cytochalasin D | 1 | 2003 | 4 | 0.050 |
Why?
|
| Thymosin | 1 | 2003 | 5 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 3904 | 0.050 |
Why?
|
| Gold | 2 | 1995 | 116 | 0.050 |
Why?
|
| Diet | 1 | 2012 | 1277 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 16 | 0.050 |
Why?
|
| Heme Oxygenase-1 | 1 | 2024 | 76 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2006 | 312 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 238 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2009 | 972 | 0.050 |
Why?
|
| Clone Cells | 2 | 1994 | 263 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2003 | 83 | 0.050 |
Why?
|
| Urine | 1 | 2003 | 64 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 946 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2005 | 316 | 0.050 |
Why?
|
| Pancreas | 1 | 2006 | 341 | 0.050 |
Why?
|
| Adherens Junctions | 1 | 2003 | 24 | 0.050 |
Why?
|
| Adaptation, Physiological | 2 | 1997 | 560 | 0.050 |
Why?
|
| Mannitol | 2 | 1994 | 40 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 119 | 0.050 |
Why?
|
| Xenopus | 1 | 2002 | 87 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2010 | 2046 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 1193 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2006 | 401 | 0.050 |
Why?
|
| von Willebrand Factor | 1 | 2003 | 85 | 0.050 |
Why?
|
| Microinjections | 1 | 2002 | 92 | 0.050 |
Why?
|
| Angiography | 1 | 2003 | 208 | 0.050 |
Why?
|
| Arterioles | 1 | 2002 | 52 | 0.040 |
Why?
|
| Phalloidine | 1 | 2001 | 3 | 0.040 |
Why?
|
| Rheology | 1 | 2002 | 94 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2003 | 269 | 0.040 |
Why?
|
| Stress Fibers | 1 | 2001 | 18 | 0.040 |
Why?
|
| Glucose | 1 | 1987 | 1048 | 0.040 |
Why?
|
| Reference Values | 2 | 1997 | 798 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 1101 | 0.040 |
Why?
|
| Glycomics | 1 | 2021 | 7 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2002 | 124 | 0.040 |
Why?
|
| Skin | 1 | 2007 | 753 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 376 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2016 | 11772 | 0.040 |
Why?
|
| Software | 1 | 2007 | 680 | 0.040 |
Why?
|
| Sample Size | 2 | 2012 | 121 | 0.040 |
Why?
|
| Diuretics | 1 | 2021 | 68 | 0.040 |
Why?
|
| Cadherins | 1 | 2003 | 200 | 0.040 |
Why?
|
| Membranes | 1 | 2001 | 13 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2006 | 573 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2005 | 1179 | 0.040 |
Why?
|
| Cell Hypoxia | 2 | 2018 | 247 | 0.040 |
Why?
|
| Scholarly Communication | 1 | 2021 | 4 | 0.040 |
Why?
|
| Video Recording | 1 | 2002 | 217 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2002 | 397 | 0.040 |
Why?
|
| Indiana | 1 | 2021 | 38 | 0.040 |
Why?
|
| Statistics as Topic | 2 | 2012 | 283 | 0.040 |
Why?
|
| Sphingomyelins | 1 | 2001 | 22 | 0.040 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 25 | 0.040 |
Why?
|
| Solute Carrier Family 12, Member 1 | 1 | 2020 | 2 | 0.040 |
Why?
|
| Inflammation | 2 | 2003 | 2878 | 0.040 |
Why?
|
| Gene Expression | 1 | 2006 | 1476 | 0.040 |
Why?
|
| Myosin Type II | 1 | 2020 | 18 | 0.040 |
Why?
|
| Uromodulin | 1 | 2020 | 22 | 0.040 |
Why?
|
| Oxygen Consumption | 2 | 2018 | 718 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2020 | 58 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 428 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2021 | 96 | 0.040 |
Why?
|
| Renal Elimination | 1 | 2020 | 5 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 155 | 0.040 |
Why?
|
| Aging | 1 | 2011 | 1969 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2003 | 558 | 0.040 |
Why?
|
| Protein Binding | 2 | 2020 | 2238 | 0.040 |
Why?
|
| Cell Fractionation | 2 | 1992 | 50 | 0.040 |
Why?
|
| Perfusion | 2 | 2011 | 251 | 0.040 |
Why?
|
| Adolescent | 1 | 2019 | 22530 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2002 | 588 | 0.040 |
Why?
|
| Shear Strength | 1 | 2019 | 73 | 0.040 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1999 | 110 | 0.040 |
Why?
|
| Urothelium | 1 | 1999 | 33 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 79 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 1581 | 0.040 |
Why?
|
| alpha-MSH | 1 | 1998 | 6 | 0.040 |
Why?
|
| Integrins | 1 | 1999 | 90 | 0.040 |
Why?
|
| Health | 1 | 1999 | 82 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2008 | 3747 | 0.030 |
Why?
|
| 3,3'-Diaminobenzidine | 1 | 1998 | 3 | 0.030 |
Why?
|
| 4-Chloro-7-nitrobenzofurazan | 1 | 1998 | 3 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1998 | 9 | 0.030 |
Why?
|
| Growth Substances | 1 | 1998 | 138 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 978 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2001 | 409 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 165 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2018 | 5216 | 0.030 |
Why?
|
| Lung | 1 | 2011 | 4106 | 0.030 |
Why?
|
| Heymann Nephritis Antigenic Complex | 1 | 1997 | 2 | 0.030 |
Why?
|
| Leucyl Aminopeptidase | 2 | 1988 | 2 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 1998 | 139 | 0.030 |
Why?
|
| Internet | 1 | 2002 | 689 | 0.030 |
Why?
|
| Rats, Inbred Dahl | 1 | 2017 | 9 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2012 | 1111 | 0.030 |
Why?
|
| Methionine | 1 | 1998 | 161 | 0.030 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2017 | 31 | 0.030 |
Why?
|
| Ceramides | 1 | 1998 | 117 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 365 | 0.030 |
Why?
|
| Peptides | 1 | 2023 | 998 | 0.030 |
Why?
|
| Ankyrins | 1 | 1996 | 11 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1997 | 99 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 209 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 1266 | 0.030 |
Why?
|
| Exocytosis | 1 | 1997 | 85 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 1997 | 206 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2012 | 1891 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2010 | 418 | 0.030 |
Why?
|
| Insulin | 1 | 2007 | 2512 | 0.030 |
Why?
|
| DNA | 1 | 2002 | 1435 | 0.030 |
Why?
|
| Program Development | 2 | 2008 | 368 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 506 | 0.030 |
Why?
|
| Prevalence | 1 | 2002 | 2865 | 0.030 |
Why?
|
| Cell Division | 1 | 1997 | 756 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2015 | 21 | 0.030 |
Why?
|
| South America | 1 | 2015 | 56 | 0.030 |
Why?
|
| Kidneys, Artificial | 1 | 1994 | 6 | 0.030 |
Why?
|
| Hematocrit | 1 | 2015 | 108 | 0.030 |
Why?
|
| Pyridones | 1 | 2016 | 209 | 0.030 |
Why?
|
| Urinary Tract Infections | 2 | 2007 | 210 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1138 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2014 | 38 | 0.030 |
Why?
|
| Ion Transport | 1 | 2014 | 62 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 115 | 0.030 |
Why?
|
| North America | 1 | 2015 | 302 | 0.030 |
Why?
|
| Models, Structural | 1 | 1993 | 41 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1995 | 405 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 418 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2014 | 67 | 0.030 |
Why?
|
| Proteome | 1 | 2018 | 514 | 0.030 |
Why?
|
| Ferritins | 1 | 1994 | 70 | 0.030 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2013 | 10 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2014 | 180 | 0.020 |
Why?
|
| Potassium | 1 | 2014 | 152 | 0.020 |
Why?
|
| Tobramycin | 1 | 1994 | 63 | 0.020 |
Why?
|
| Injections | 1 | 2014 | 199 | 0.020 |
Why?
|
| Acidosis | 1 | 1994 | 105 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1995 | 239 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2014 | 138 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 174 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2020 | 3124 | 0.020 |
Why?
|
| Neutrophils | 1 | 1999 | 1124 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 264 | 0.020 |
Why?
|
| Type C Phospholipases | 1 | 1993 | 69 | 0.020 |
Why?
|
| Phosphatidylinositols | 1 | 1993 | 57 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 1994 | 1048 | 0.020 |
Why?
|
| Bowman Capsule | 1 | 2012 | 1 | 0.020 |
Why?
|
| Patient Safety | 1 | 2016 | 356 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 762 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2012 | 70 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 1996 | 728 | 0.020 |
Why?
|
| Ruthenium Red | 1 | 1991 | 7 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 1991 | 37 | 0.020 |
Why?
|
| Permeability | 1 | 2012 | 169 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 1991 | 85 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 196 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2012 | 143 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2011 | 149 | 0.020 |
Why?
|
| Fimbriae Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| ADP-Ribosylation Factor 1 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Haiti | 1 | 2010 | 14 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 50 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2010 | 49 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 67 | 0.020 |
Why?
|
| Carcinogens | 1 | 2011 | 123 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1993 | 938 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 2028 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 2011 | 108 | 0.020 |
Why?
|
| Transportation | 1 | 2010 | 57 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 63 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1349 | 0.020 |
Why?
|
| Activated Protein C Resistance | 1 | 2009 | 3 | 0.020 |
Why?
|
| Citrates | 1 | 1989 | 41 | 0.020 |
Why?
|
| Sodium Isotopes | 1 | 2009 | 2 | 0.020 |
Why?
|
| Lipids | 1 | 2015 | 707 | 0.020 |
Why?
|
| Age Factors | 2 | 2008 | 3342 | 0.020 |
Why?
|
| Kidney Medulla | 1 | 2009 | 31 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 559 | 0.020 |
Why?
|
| Protective Agents | 1 | 2009 | 42 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 474 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2010 | 176 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 1989 | 103 | 0.020 |
Why?
|
| Hepcidins | 1 | 2009 | 21 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2009 | 66 | 0.020 |
Why?
|
| Lipocalins | 1 | 2009 | 35 | 0.020 |
Why?
|
| Cellulose | 1 | 1989 | 58 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1989 | 78 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2008 | 17 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2008 | 11 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2009 | 80 | 0.020 |
Why?
|
| Adenylyl Cyclases | 1 | 1988 | 60 | 0.020 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2009 | 81 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2011 | 385 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 1989 | 135 | 0.020 |
Why?
|
| Chemokines | 1 | 2009 | 217 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 552 | 0.020 |
Why?
|
| Blood Volume | 1 | 2008 | 65 | 0.020 |
Why?
|
| Developed Countries | 1 | 2008 | 38 | 0.020 |
Why?
|
| Phlorhizin | 1 | 1987 | 2 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 518 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 462 | 0.020 |
Why?
|
| Cimetidine | 1 | 2007 | 12 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 1992 | 649 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2007 | 53 | 0.020 |
Why?
|
| Filtration | 1 | 2007 | 68 | 0.020 |
Why?
|
| Proton-Translocating ATPases | 1 | 2007 | 5 | 0.020 |
Why?
|
| Cations | 1 | 2007 | 83 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 627 | 0.020 |
Why?
|
| Urea | 1 | 2007 | 85 | 0.020 |
Why?
|
| Renin-Angiotensin System | 1 | 2007 | 80 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2007 | 123 | 0.020 |
Why?
|
| Endotoxemia | 1 | 2007 | 86 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1985 | 36 | 0.010 |
Why?
|
| Risk | 1 | 2008 | 919 | 0.010 |
Why?
|
| Hexosaminidases | 1 | 1985 | 17 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2007 | 181 | 0.010 |
Why?
|
| Receptor, TIE-2 | 1 | 2005 | 11 | 0.010 |
Why?
|
| NADH Dehydrogenase | 1 | 1985 | 20 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 8333 | 0.010 |
Why?
|
| Peritonitis | 1 | 2006 | 83 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2007 | 216 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 624 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2005 | 58 | 0.010 |
Why?
|
| Laminin | 1 | 2005 | 72 | 0.010 |
Why?
|
| Succinate Dehydrogenase | 1 | 1985 | 65 | 0.010 |
Why?
|
| Developing Countries | 1 | 2008 | 316 | 0.010 |
Why?
|
| Xenopus Proteins | 1 | 2005 | 36 | 0.010 |
Why?
|
| Health Surveys | 1 | 2007 | 518 | 0.010 |
Why?
|
| Multiple Organ Failure | 1 | 2006 | 120 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2006 | 85 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 246 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2005 | 112 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 977 | 0.010 |
Why?
|
| Focus Groups | 1 | 2008 | 569 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2007 | 618 | 0.010 |
Why?
|
| Adsorption | 2 | 1995 | 153 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 156 | 0.010 |
Why?
|
| Neoplasms | 1 | 2020 | 2906 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2011 | 1356 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 396 | 0.010 |
Why?
|
| Binding Sites | 1 | 2007 | 1310 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2006 | 199 | 0.010 |
Why?
|
| Smoking | 1 | 2011 | 1472 | 0.010 |
Why?
|
| Communication | 1 | 2010 | 975 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 1987 | 857 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 286 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1987 | 529 | 0.010 |
Why?
|
| Vasodilation | 1 | 2007 | 521 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 767 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2970 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2003 | 42 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 112 | 0.010 |
Why?
|
| Propidium | 1 | 2002 | 8 | 0.010 |
Why?
|
| Fixatives | 1 | 2002 | 13 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 457 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2001 | 17291 | 0.010 |
Why?
|
| Comorbidity | 1 | 2008 | 1661 | 0.010 |
Why?
|
| Formaldehyde | 1 | 2002 | 65 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2007 | 892 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 617 | 0.010 |
Why?
|
| Medicare | 1 | 2006 | 903 | 0.010 |
Why?
|
| Sex Factors | 1 | 2006 | 2105 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2002 | 716 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1997 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2597 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3542 | 0.010 |
Why?
|
| Child | 2 | 2008 | 22707 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1995 | 62 | 0.010 |
Why?
|
| Diffusion | 1 | 1995 | 120 | 0.010 |
Why?
|
| Acrylic Resins | 1 | 1994 | 46 | 0.010 |
Why?
|
| Amyloidosis | 1 | 1994 | 44 | 0.010 |
Why?
|
| Cattle | 1 | 1995 | 946 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 1997 | 1038 | 0.010 |
Why?
|
| Jejunum | 1 | 1989 | 37 | 0.000 |
Why?
|
| Citric Acid | 1 | 1989 | 33 | 0.000 |
Why?
|
| Duodenum | 1 | 1989 | 77 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1989 | 354 | 0.000 |
Why?
|